We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement
News

Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement

Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement
News

Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cobra Biologics and Alligator Bioscience AB Sign Monoclonal Antibody Manufacturing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cobra Biologics and Alligator Bioscience AB have announced that they have entered into a manufacturing services and supply agreement for the production of monoclonal antibody Drug Substance and Drug Product for pre-clinical studies and Phase I-II clinical trials.

Under the terms of the agreement, Cobra will be providing cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP supplies, as well as stability studies and QP release for clinical trials.

Peter Coleman, CEO of Cobra Biologics said: "Having been through a rigorous selection process, we are very pleased to have been chosen by Alligator. We believe that our comprehensive service offering, right from our excellent cell line development capability through to fill/finish at our recently acquired Matfors facility (Sweden) enabled us to win this important program with Alligator in a highly competitive market place. We look forward to building a lasting relationship with Alligator Bioscience.”

Alligator will be taking advantage of Cobra’s maxXpress service, which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team and the Cello™ robotic clone selection system, to enable rapid clone selection and production of the monoclonal antibody.

Advertisement